207 related articles for article (PubMed ID: 37931247)
1. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer.
Yan W; Menjivar RE; Bonilla ME; Steele NG; Kemp SB; Du W; Donahue KL; Brown KL; Carpenter ES; Avritt FR; Irizarry-Negron VM; Yang S; Burns WR; Zhang Y; Pasca di Magliano M; Bednar F
Cancer Immunol Res; 2024 Jan; 12(1):91-106. PubMed ID: 37931247
[TBL] [Abstract][Full Text] [Related]
2. Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer.
Yan W; Steele NG; Kemp SB; Menjivar RE; Du W; Carpenter ES; Donahue KL; Brown KL; Irizarry-Negron V; Yang S; Burns WR; Zhang Y; di Magliano MP; Bednar F
bioRxiv; 2023 Jan; ():. PubMed ID: 36711890
[TBL] [Abstract][Full Text] [Related]
3. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
4. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
5. Targeting TNF-α-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling.
Dixit A; Sarver A; Zettervall J; Huang H; Zheng K; Brekken RA; Provenzano PP
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36256464
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling pathway in pancreatic tumorigenesis.
Chung WC; Xu K
Adv Cancer Res; 2023; 159():1-36. PubMed ID: 37268393
[TBL] [Abstract][Full Text] [Related]
7. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
8. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
Rohila D; Park IH; Pham TV; Weitz J; Hurtado de Mendoza T; Madheswaran S; Ishfaq M; Beaman C; Tapia E; Sun S; Patel J; Tamayo P; Lowy AM; Joshi S
Cancer Res; 2023 Aug; 83(16):2675-2689. PubMed ID: 37306759
[TBL] [Abstract][Full Text] [Related]
9. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
[TBL] [Abstract][Full Text] [Related]
10. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting.
Cheung PF; Neff F; Neander C; Bazarna A; Savvatakis K; Liffers ST; Althoff K; Lee CL; Moding EJ; Kirsch DG; Saur D; Bazhin AV; Trajkovic-Arsic M; Heikenwalder MF; Siveke JT
Cancer Res; 2018 Sep; 78(17):4997-5010. PubMed ID: 29844119
[TBL] [Abstract][Full Text] [Related]
11. VentX expression in tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers.
Le Y; Gao H; Richards W; Zhao L; Bleday R; Clancy T; Zhu Z
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573491
[TBL] [Abstract][Full Text] [Related]
12. Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Pathway.
Li H; Zhu R; Liu X; Zhao K; Hong D
Oxid Med Cell Longev; 2022; 2022():3341038. PubMed ID: 36105484
[TBL] [Abstract][Full Text] [Related]
13. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
[TBL] [Abstract][Full Text] [Related]
14. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
[TBL] [Abstract][Full Text] [Related]
15. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Seifert L; Werba G; Tiwari S; Giao Ly NN; Alothman S; Alqunaibit D; Avanzi A; Barilla R; Daley D; Greco SH; Torres-Hernandez A; Pergamo M; Ochi A; Zambirinis CP; Pansari M; Rendon M; Tippens D; Hundeyin M; Mani VR; Hajdu C; Engle D; Miller G
Nature; 2016 Apr; 532(7598):245-9. PubMed ID: 27049944
[TBL] [Abstract][Full Text] [Related]
16. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway.
Sun L; Zhang X; Song Q; Liu L; Forbes E; Tian W; Zhang Z; Kang Y; Wang H; Fleming JB; Pasche BC; Zhang W
Cancer Lett; 2021 Mar; 500():132-146. PubMed ID: 33309859
[TBL] [Abstract][Full Text] [Related]
17. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma.
Daley D; Mani VR; Mohan N; Akkad N; Pandian GSDB; Savadkar S; Lee KB; Torres-Hernandez A; Aykut B; Diskin B; Wang W; Farooq MS; Mahmud AI; Werba G; Morales EJ; Lall S; Wadowski BJ; Rubin AG; Berman ME; Narayanan R; Hundeyin M; Miller G
J Exp Med; 2017 Jun; 214(6):1711-1724. PubMed ID: 28442553
[TBL] [Abstract][Full Text] [Related]
18. Sphingomyelin synthase 2 is a positive regulator of the CSF1R-STAT3 pathway in pancreatic cancer-associated macrophage.
He S; Gu X; Yang J; Xu F; Hu J; Wang W; Huang Y; Lou B; Ding T; Zhou L; Ye D; Yu K; Dong J
Front Pharmacol; 2022; 13():902016. PubMed ID: 36324684
[No Abstract] [Full Text] [Related]
19. The pancreas cancer microenvironment.
Feig C; Gopinathan A; Neesse A; Chan DS; Cook N; Tuveson DA
Clin Cancer Res; 2012 Aug; 18(16):4266-76. PubMed ID: 22896693
[TBL] [Abstract][Full Text] [Related]
20. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
